Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company's product portfolio includes MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
Market Cap | 15.892 Million | Shares Outstanding | 42.722 Million | Avg 30-day Volume | 97.561 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.46 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -45.788 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | -19.579 Million |
Current Ratio | 17.15 | EPS Growth | -8.933 | Quick Ratio | 16.919 |
1 Yr BETA | 0.8514 | 52-week High/Low | 3.24 / 0.33 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 15.5649 | Altman Z-Score | -7.782 | Free Cash Flow to Firm | -11.176 Million |
Earnings Report | 2022-08-01 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
180,000 | 2022-02-16 | 1 | |
RACE GEOFF PRESIDENT |
|
200,000 | 2022-02-16 | 1 |
LUTHRINGER REMY CEO |
|
505,000 | 2022-02-16 | 1 |
|
191,488 | 2021-12-01 | 2 | |
|
20,000 | 2021-06-11 | 1 | |
|
40,000 | 2021-06-11 | 1 | |
|
20,000 | 2021-06-11 | 1 | |
|
20,000 | 2021-06-11 | 1 | |
|
20,000 | 2021-06-11 | 1 | |
REILLY JOSEPH H. SVP & CHIEF OPERATING OFFICER |
|
31,747 | 2020-12-14 | 0 |
DAVIDSON MICHAEL CHIEF MEDICAL OFFICER |
|
0 | 2020-10-13 | 0 |
SAOUD JAY SVP AND HEAD OF R&D |
|
0 | 2020-10-13 | 0 |
SMITH DEVIN WHITTEMORE SVP AND GENERAL COUNSEL |
|
0 | 2020-10-13 | 0 |
RUSSELL RICHARD E. PRESIDENT |
|
0 | 2020-06-19 | 0 |
INDEX VENTURE ASSOCIATES III LTD INDEX VENTURE ASSOCIATES IV LTD |
|
No longer subject to file | 2019-06-24 | 0 |
|
0 | 2018-01-31 | 0 | |
|
No longer subject to file | 2017-08-29 | 0 | |
|
No longer subject to file | 2017-07-24 | 0 | |
LEVINE MARK S. SVP,GENERAL COUNSEL & SEC. |
|
0 | 2017-06-01 | 0 |
|
4,690,906 | 2016-12-12 | 0 | |
|
4,690,906 | 2016-12-12 | 0 | |
|
No longer subject to file | 2015-03-18 | 0 | |
|
10,112,713 | 2014-07-07 | 0 | |
VIVALDI COELHO ROGERIO PRESIDENT AND CEO |
|
540,288 | 2014-06-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 22:15:03 UTC | 0.3412 | 0.4788 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 21:45:03 UTC | 0.3412 | 0.4788 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 21:15:03 UTC | 0.3412 | 0.4788 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 20:45:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 20:15:05 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 19:45:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 19:15:04 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 18:45:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 18:15:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 17:45:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 17:15:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 16:45:04 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 16:15:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 15:45:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 15:15:03 UTC | 0.3356 | 0.4844 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 14:45:03 UTC | 0.3338 | 0.4862 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 14:15:04 UTC | 0.3338 | 0.4862 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 13:45:03 UTC | 0.3338 | 0.4862 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 13:15:03 UTC | 0.3338 | 0.4862 | 400000 |
MINERVA NEUROSCIENCES INC NERV | 2022-05-20 12:45:03 UTC | 0.3338 | 0.4862 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|